Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

A pan-cancer diagnostic platform based on nanobiotechnology and machine learning for simple and accessible early cancer detection

Project description

Simple, accessible early cancer detection

Cancer caught early can be treated effectively, resulting in survival rates of over 80 per cent. If it isn't, then survival rates drop as low as 17 per cent. More than half of the cancer deaths recorded to date are due to the lack of preventive testing. Costly MRI imagery, for example, lacks detection capability until cancer symptoms and tumour growths set in. Metachip, produced by ConquerX, is a revolutionary pan-cancer diagnostic platform that enables early-stage detection for the 10 most common types of cancer. Metachip is a diagnostic software suite powered by cutting edge artificial intelligence. It is cost effective and administered through a single, simple blood test that does not require special lab facilities and analytic techniques.

Objective

Cancer is the second highest cause of death in the EU, with more than 1.3 million deaths attributable to cancer each year. Early detection of cancer is crucial to increasing the chances of survival for patients. For example, the average cancer survival rate is 83% when caught early and only 17% when diagnosed at an advanced stage. This is compounded by the difficulty and expense of screening for early stage cancers. Beyond expensive and specialist whole body imaging techniques such as MRI, there is still no commercially available general test for detecting any type of cancer before symptoms present themselves. Staggeringly, 52% of cancer deaths are due to a lack of preventative tests. Metachip, from ConquerX, is a revolutionary pan-cancer diagnostic platform that enables early-stage detection of the 10 most common types of cancer from a single, simple blood test. The platform consists of a reading device, disposable chips coated with a proprietary nanocomposite, and a diagnostic software suite powered by cutting edge artificial intelligence. The Metachip test is cost effective, fast (one hour to results), and does not require specialist analytical techniques or lab facilities. By delivering the Metachip platform, ConquerX aim to make early-stage detection of cancer available to every hospital in the EU and worldwide. During the phase 1 feasibility study, ConquerX will establish a sound go-to-market strategy and supply chain, and will draft further development plans. During the second phase of the innovation project, ConquerX will optimise the diagnostic platform, scale-up manufacturing, perform clinical validation activities with partner hospitals and gain regulatory approval.

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

SME-1 - SME instrument phase 1

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

CQX LAB UK LTD
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 50 000,00
Address
UNIT 6 QUEENS YARD, WHITE POST LANE
E9 5EN LONDON
United Kingdom

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
London Inner London — East Tower Hamlets
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 71 429,00
My booklet 0 0